The GHG protocol categorizes emissions into three scopes: Scope 1 for direct emissions, Scope 2 for indirect emissions from purchased electricity, and Scope 3 for other indirect emissions.
For pharmaceutical companies, Scope 3 emissions often make up over 90% of the total, presenting a significant challenge for direct action.
However, addressing Scope 1 and Scope 2 emissions can have a ripple effect, positively impacting Scope 3 emissions throughout the supply chain.
Our experts explain, through the following article, the engineering solutions studied and applied for a recent case study of a new biotech pharmaceutical facility.
Read the article to discover the implemented actions and their impact in terms of emissions reduction.
Articoli correlati
April 19, 2024
Towards a greener pharmaceutical industry: Energy efficiency
Energy efficiency first is a guiding principle widely used in EU policies…
September 28, 2023
The contribution of CFD simulation to sustainability in the pharmaceutical industry
Computational fluid dynamics (CFD) simulation has emerged as a powerful tool...
September 21, 2023
Sustainability in the Life Sciences industry: a few considerations
Healthcare manufacturing stands out as a significant contributor to greenhouse…